Try our Advanced Search for more refined results
Azurity Pharmaceuticals Inc.
-
Order | Filed: May 15, 2024 | Entered: May 15, 2024 Azurity Pharmaceuticals, Inc. et al v. Zydus Pharmaceuticals (USA) Inc. et al
Patent - Abbreviated New Drug Application(ANDA) | Delaware
Oral Order
ORAL ORDER - IT IS HEREBY ORDERED that, within thirty (30) days from the date of this Order, the parties shall confer regarding proposed dates in the scheduling order and shall submit a proposed order, which is also consistent with the following guidance. A Bench Trial will be set to begin on 6/2/2025. The parties shall provide final contentions (i.e., final infringement and invalidity contentions, as well as final non-infringement and validity contentions) around the time that fact discovery closes (i.e., several weeks prior to or after the deadline to complete fact discovery) and at least three weeks before Plaintiffs serve their opening claim construction brief. Final contentions shall include a party's contentions under its proposed construction(s), as well as under the opposing construction(s) (if such an alternative contention exists). As such, the parties are encouraged to exchange proposed claim terms and proposed constructions early in the case but in no event later than necessary to allow the parties to include alternative contentions in their final contentions. The joint claim construction chart shall be due one week after the parties have completed their exchange of final contentions, and the joint claim construction brief must be filed at least three weeks before the claim construction hearing. The parties shall leave at least three weeks between the claim construction hearing and the opening of expert discovery. The parties are to use the Court's form scheduling order, which is posted at http://www.ded.uscourts.gov (see Chambers, Judge Noreika, Forms), and the parties must include a proposal for the length and timing of trial. If there are disputes or issues that the Court needs to address in the proposed scheduling order, the parties shall direct the Court to the paragraph numbers in which those appear in a cover letter to the Court. ORDERED by Judge Maryellen Noreika on 5/15/2024. (dlw)
-
Misc | Filed: May 14, 2024 | Entered: May 14, 2024 Azurity Pharmaceuticals, Inc. et al v. Teva Pharmaceuticals, Inc.
Patent - Abbreviated New Drug Application(ANDA) | Delaware
Patent/Trademark Report to Commissioner of Patents
Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s). (Attachments: # 1 Stipulation of Dismissal)(mdb)
-
Misc | Filed: May 14, 2024 | Entered: May 14, 2024 AZURITY PHARMACEUTICALS, INC. v. BIONPHARMA INC.
Patent - Abbreviated New Drug Application(ANDA) | Delaware
Letter
[SEALED] Letter to The Honorable Mitchell S. Goldberg from Megan E. Dellinger regarding -- Answering Letter Brief Regarding Discovery Disputes -- - re 503 Letter,. (Attachments: # 1 Ex. 1, # 2 Ex. 2)(Dellinger, Megan)
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
- Archive of over 450,000 articles
- Database of over 2.1 million cases
- 62,000+ organization-specific pages.
- Daily and real-time news and case alerts on organizations, industries, and customized search queries.
- Significant legal events involving law firms, companies, industries, and government agencies.
- Learn more
TRY LAW360 FREE FOR SEVEN DAYS
Already a subscriber? Click here to login